We provide you with 20 years of free, institutional-grade data for RXRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RXRX. Explore the full financial landscape of RXRX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$5,251,798
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Gibson Christopher | Sale | -100,000 | $4.76 | $476,000 | 2025-09-26 |
| Taylor Ben R | Sale | -7,057 | $4.83 | $34,085 | 2025-09-17 |
| Gibson Christopher | Sale | -100,000 | $4.71 | $471,000 | 2025-09-12 |
| Gibson Christopher | Conversion | 120,000 | 2025-09-12 | ||
| Gibson Christopher | Sale | -100,000 | $4.84 | $484,000 | 2025-08-28 |
| Gibson Christopher | Conversion | 100,000 | 2025-08-28 | ||
| Khan Najat | Sale | -40,388 | $5.64 | $227,788 | 2025-08-19 |
| Gibson Christopher | Sale | -40,390 | $5.64 | $227,800 | 2025-08-19 |
| Taylor Ben R | Sale | -11,908 | $5.64 | $67,161 | 2025-08-19 |
| Gibson Christopher | Sale | -17,875 | $5.28 | $94,380 | 2025-08-13 |
| Gibson Christopher | Conversion | 17,875 | 2025-08-13 | ||
| Gibson Christopher | Sale | -100,000 | $5.28 | $528,000 | 2025-08-13 |
| Gibson Christopher | Conversion | 100,000 | 2025-08-13 | ||
| Gibson Christopher | Sale | -500,300 | $5.28 | $2,641,584 | 2025-08-13 |
| Gibson Christopher | Conversion | 423,666 | 2025-08-13 | ||
| Dar Zavain | Grant, award...etc | 2,924 | 2025-07-03 | ||
| Li Dean Y | Grant, award...etc | 1,949 | 2025-07-03 | ||
| Li Dean Y | Grant, award...etc | 22,016 | 2025-06-23 | ||
| Bumpus Namandje | Grant, award...etc | 11,008 | 2025-06-23 | ||
| Sun Elaine D | Grant, award...etc | 11,008 | 2025-06-23 | ||
| Michor Franziska | Grant, award...etc | 22,016 | 2025-06-23 | ||
| HERSHBERG ROBERT | Grant, award...etc | 22,016 | 2025-06-23 | ||
| Dar Zavain | Grant, award...etc | 22,016 | 2025-06-23 | ||
| Borgeson Blake | Grant, award...etc | 22,016 | 2025-06-23 | ||
| Taylor Ben R | Sale | -7,057 | $4.92 | $34,720 | 2025-06-18 |
| Taylor Ben R | Sale | -11,908 | $4.25 | $50,609 | 2025-05-19 |
| Khan Najat | Sale | -3,796 | $4.25 | $16,133 | 2025-05-19 |
| Gibson Christopher | Sale | -36,197 | $4.25 | $153,837 | 2025-05-19 |
| Dar Zavain | Grant, award...etc | 2,745 | 2025-04-03 | ||
| Taylor Ben R | Sale | -26,571 | $5.09 | $135,379 | 2025-04-03 |
| Li Dean Y | Grant, award...etc | 2,268 | 2025-04-03 | ||
| Gibson Christopher | Sale | -138,574 | $6.04 | $836,987 | 2025-03-28 |
| Taylor Ben R | Sale | -7,057 | $6.84 | $48,270 | 2025-03-19 |
| Bumpus Namandje | Grant, award...etc | 36,549 | 2025-03-19 | ||
| Sun Elaine D | Grant, award...etc | 36,549 | 2025-03-19 | ||
| Gibson Christopher | Sale | -40,000 | $6.58 | $263,200 | 2025-03-07 |
| Gibson Christopher | Conversion | 40,000 | 2025-03-07 | ||
| Taylor Ben R | Sale | -10,879 | $10.64 | $115,753 | 2025-02-20 |
| Gibson Christopher | Sale | -17,132 | $10.64 | $182,284 | 2025-02-20 |
| Gibson Christopher | Sale | -40,000 | $7.68 | $307,200 | 2025-02-07 |
| Gibson Christopher | Conversion | 40,000 | 2025-02-07 | ||
| Taylor Ben R | Sale | -6,544 | $7.25 | $47,444 | 2025-02-05 |
| Taylor Ben R | Grant, award...etc | 48,940 | 2025-02-05 | ||
| Gibson Christopher | Sale | -5,569 | $7.25 | $40,375 | 2025-02-05 |
| Gibson Christopher | Grant, award...etc | 542,092 | 2025-02-05 | ||
| Khan Najat | Sale | -2,753 | $7.25 | $19,959 | 2025-02-05 |
| Khan Najat | Grant, award...etc | 218,162 | 2025-02-05 | ||
| Gibson Christopher | Sale | -40,000 | $7.31 | $292,400 | 2025-01-13 |
| Gibson Christopher | Conversion | 40,000 | 2025-01-13 | ||
| Li Dean Y | Grant, award...etc | 1,647 | 2025-01-06 | ||
| Dar Zavain | Grant, award...etc | 1,907 | 2025-01-06 | ||
| Borgeson Blake | Grant, award...etc | 1,734 | 2025-01-06 | ||
| Taylor Ben R | Grant, award...etc | 370,343 | 2024-12-20 | ||
| Taylor Ben R | Sale | -22,725 | $6.04 | $137,259 | 2024-12-18 |
| Gibson Christopher | Sale | -40,000 | $7.16 | $286,400 | 2024-12-06 |
| Gibson Christopher | Conversion | 40,000 | 2024-12-06 | ||
| Taylor Ben R | Initial | 2024-12-02 | |||
| Michor Franziska | Grant, award...etc | 105,037 | 2024-11-22 | ||
| Secora Michael | Sale | -11,937 | $6.17 | $73,711 | 2024-11-19 |
| Marriott Tina | Sale | -14,286 | $6.17 | $88,216 | 2024-11-19 |
| Gibson Christopher | Sale | -26,023 | $6.17 | $160,692 | 2024-11-19 |
| Mauro David J | Sale | -4,187 | $6.17 | $25,855 | 2024-11-19 |
| Gibson Christopher | Sale | -40,000 | $7.74 | $309,600 | 2024-11-15 |
| Gibson Christopher | Conversion | 40,000 | 2024-11-15 | ||
| Borgeson Blake | Sale | -11,447 | $7.64 | $87,457 | 2024-11-14 |
| Secora Michael | Sale | -30,000 | $7.64 | $229,257 | 2024-11-14 |
| Secora Michael | Derivatives Exercise | 78,750 | 2024-11-14 | ||
| Borgeson Blake | Sale | -11,447 | $6.72 | $76,926 | 2024-10-31 |
| Marriott Tina | Sale | -6,000 | $6.31 | $37,855 | 2024-10-28 |
| Marriott Tina | Derivatives Exercise | 6,000 | 2024-10-28 | ||
| Borgeson Blake | Sale | -11,447 | $6.67 | $76,326 | 2024-10-17 |
| Secora Michael | Sale | -30,000 | $6.32 | $189,513 | 2024-10-10 |
| Secora Michael | Derivatives Exercise | 78,750 | 2024-10-10 | ||
| Dar Zavain | Grant, award...etc | 2,229 | 2024-10-04 | ||
| Gibson Christopher | Sale | -40,000 | $6.16 | $246,400 | 2024-10-04 |
| Gibson Christopher | Conversion | 40,000 | 2024-10-04 | ||
| Borgeson Blake | Grant, award...etc | 2,026 | 2024-10-04 | ||
| Li Dean Y | Grant, award...etc | 1,925 | 2024-10-04 | ||
| Borgeson Blake | Sale | -11,447 | $6.22 | $71,150 | 2024-10-03 |
| Marriott Tina | Sale | -6,000 | $7 | $42,005 | 2024-09-30 |
| Marriott Tina | Derivatives Exercise | 6,000 | 2024-09-30 | ||
| Borgeson Blake | Sale | -11,447 | $6.84 | $78,333 | 2024-09-19 |
| Secora Michael | Sale | -30,000 | $6.17 | $184,998 | 2024-09-12 |
| Secora Michael | Derivatives Exercise | 78,750 | 2024-09-12 | ||
| Gibson Christopher | Sale | -40,000 | $6.04 | $241,600 | 2024-09-06 |
| Gibson Christopher | Conversion | 40,000 | 2024-09-06 | ||
| Borgeson Blake | Sale | -11,447 | $6.27 | $71,718 | 2024-09-05 |
| Marriott Tina | Sale | -6,000 | $7.56 | $45,376 | 2024-09-03 |
| Marriott Tina | Derivatives Exercise | 6,000 | 2024-09-03 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-30 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-29 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-28 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-27 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-26 | ||
| Gibson Christopher | Derivatives Exercise | 5,000 | 2024-08-23 | ||
| Borgeson Blake | Sale | -11,447 | $7.12 | $81,532 | 2024-08-22 |
| Secora Michael | Sale | -11,962 | $6.69 | $80,026 | 2024-08-19 |
| Mauro David J | Sale | -14,146 | $6.69 | $94,637 | 2024-08-19 |
| Marriott Tina | Sale | -14,319 | $6.69 | $95,794 | 2024-08-19 |
| Gibson Christopher | Sale | -26,082 | $6.69 | $174,489 | 2024-08-19 |
| Secora Michael | Sale | -30,000 | $6.35 | $190,365 | 2024-08-15 |
| Secora Michael | Derivatives Exercise | 78,750 | 2024-08-15 | ||
| Gibson Christopher | Sale | -50,000 | $7.1 | $355,000 | 2024-08-09 |
| Gibson Christopher | Conversion | 50,000 | 2024-08-09 | ||
| Borgeson Blake | Sale | -11,447 | $6.82 | $78,083 | 2024-08-08 |
| Khan Najat | Grant, award...etc | 496,972 | 2024-08-05 | ||
| Marriott Tina | Sale | -6,000 | $8.13 | $48,809 | 2024-07-29 |
| Marriott Tina | Derivatives Exercise | 6,000 | 2024-07-29 | ||
| Borgeson Blake | Sale | -11,447 | $8.48 | $97,041 | 2024-07-25 |
The information provided in this report about RXRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Recursion Pharmaceuticals, Inc.(NASDAQ:RXRX) 
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rar...
Website: http://www.recursion.com
Founded: 2013
CEO: Chris Gibson
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends